絞り込み

16639

広告

「elotuzumab」の検索結果

246件中 61件~80件表示    検索結果をPubMedで見る PubMedで見る

Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.

Current use of monoclonal antibodies in the treatment of multiple myeloma.

[The most recent developments in diagnosis and treatment of multiple myeloma].

Antibody dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab.

Elotuzumab-induced interstitial lung disease: the first case report.

Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy.

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4).

Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling.

Elotuzumab and Dexamethasone for Relapsed or Refractory Multiple Myeloma Patients: A Retrospective Study.

A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis.

Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies.

A case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma.

The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma.

PD-1 blockade enhances elotuzumab efficacy in mouse tumor models.

Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States.

Evaluating Oncology Value-Based Frameworks in the U.S. Marketplace and Challenges in Real-World Application: A Multiple Myeloma Test Case.

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Functional Imaging with 18F-FDG PET/CT and Diffusion Weighted Imaging (DWI) in Early Response Evaluation of Combination Therapy of Elotuzumab, Lenalidomide, and Dexamethasone in a Relapsed Multiple Myeloma Patient.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります